Roles of dopamine receptors and their antagonist thioridazine in hepatoma metastasis

OncoTargets and Therapy

Volumn 8, Issue , 2015, Pages 1543-1551

  Lu, Meiling ^a   Li, Jinghua ^a   Luo, Zaili ^b,c   Zhang, Shuai ^c   Xue, Shaobo ^a   Wang, Kesheng ^a   Shi, Yan ^a   Zhang, Cunzhen ^c   Chen, Haiyang ^c   Li, Zhong ^a,d  

^a TONGJI UNIVERSITY   (China)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

^c FUDAN UNIVERSITY   (China)

^d Zhangjiang Center for Translational Medicine   (China)

Author keywords

Antipsychotic; Dopamine receptors; HCC; Metastasis; Thioridazine

Indexed keywords

EID: 84934267684     PISSN: None     EISSN: 11786930     Source Type: Journal    
DOI: 10.2147/OTT.S77373     Document Type: Article

References (32)

1. Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127:2893-2917.
2. Poon D, Anderson BO, Chen LT, et al. Management of hepatocellular carcinoma in Asia: consensus statement from the Asian Oncology Summit 2009. Lancet Oncol. 2009;10:1111-1118.
3. Yeh TC, Chiang PC, Li TK, et al. Genistein induces apoptosis in human hepatocellular carcinomas via interaction of endoplasmic reticulum stress and mitochondrial insult. Biochem Pharmacol. 2007;73:782-792.
4. Zhukovsky DS. Fever and sweats in the patient with advanced cancer. Hematol Oncol Clin North Am. 2002;16:579-588; viii.
5. Ly KL, Chidgey J, Addington-Hall J, Hotopf M. Depression in palliative care: a systematic review. Part 2. Treatment. Palliat Med. 2002;16: 279-284.
6. Mu J, Xu H, Yang Y, et al. Thioridazine, an antipsychotic drug, elicits potent antitumor effects in gastric cancer. Oncol Rep. 2014;31:2107-2114.
7. Kang S, Dong SM, Kim BR, et al. Thioridazine induces apoptosis by targeting the PI3K/Akt/mTOR pathway in cervical and endometrial cancer cells. Apoptosis. 2012;17:989-997.
8. Strobl JS, Kirkwood KL, Lantz TK, et al. Inhibition of human breast cancer cell proliferation in tissue culture by the neuroleptic agents pimozide and thioridazine. Cancer Res. 1990;50:5399-5405.
9. Gil-Ad I, Shtaif B, Levkovitz Y, et al. Characterization of phenothiazine-induced apoptosis in neuroblastoma and glioma cell lines: clinical relevance and possible application for brain-derived tumors. J Mol Neurosci. 2004;22:189-198.
10. Zhelev Z, Ohba H, Bakalova R, et al. Phenothiazines suppress proliferation and induce apoptosis in cultured leukemic cells without any influence on the viability of normal lymphocytes. Phenothiazines and leukemia. Cancer Chemother Pharmacol. 2004;53:267-275.
11. Rho SB, Kim BR, Kang S. A gene signature-based approach identifies thioridazine as an inhibitor of phosphatidylinositol-3′-kinase (PI3K)/AKT pathway in ovarian cancer cells. Gynecol Oncol. 2011;120:121-127.
12. Byun HJ, Lee JH, Kim BR, et al. Anti-angiogenic effects of thioridazine involving the FAK-mTOR pathway. Microvasc Res. 2012;84:227-234.
13. Ke XY, Lin Ng VW, Gao SJ, et al. Co-delivery of thioridazine and doxorubicin using polymeric micelles for targeting both cancer cells and cancer stem cells. Biomaterials. 2014;35:1096-1108.
14. Tuynder M, Fiucci G, Prieur S, et al. Translationally controlled tumor protein is a target of tumor reversion. Proc Natl Acad Sci U S A. 2004;101:15364-15369.
15. Amson R, Karp JE, Telerman A. Lessons from tumor reversion for cancer treatment. Curr Opin Oncol. 2013;25:59-65.
16. Sachlos E, Risueno RM, Laronde S, et al. Identification of drugs including a dopamine receptor antagonist that selectively target cancer stem cells. Cell. 2012;149:1284-1297.
17. Neto LV, Machado Ede O, Luque RM et al. Expression analysis of dopamine receptor subtypes in normal human pituitaries, nonfunctioning pituitary adenomas and somatotropinomas, and the association between dopamine and somatostatin receptors with clinical response to octreotide-LAR in acromegaly. J Clin Endocrinol Metab. 2009;94(6):1931-1937.
18. Li L, Miyamoto M, Ebihara Y, et al. DRD2/DARPP-32 expression correlates with lymph node metastasis and tumor progression in patients with esophageal squamous cell carcinoma. World J Surg. 2006;30:1672-1679; discussion 80-81.
19. Chakroborty D, Sarkar C, Basu B, et al. Catecholamines regulate tumor angiogenesis. Cancer Res. 2009;69:3727-3730.
20. Moreno-Smith M, Lee SJ, Lu C, et al. Biologic effects of dopamine on tumor vasculature in ovarian carcinoma. Neoplasia. 2013;15:502-510.
21. Moreno-Smith M, Lu C, Shahzad MM, et al. Dopamine blocks stress-mediated ovarian carcinoma growth. Clin Cancer Res. 2011;17: 3649-3659.
22. Boni R, Lichtensteiger W, Steinert HC, et al. D1 dopamine receptors are not expressed in human melanoma. Melanoma Res. 1997;7:117-119.
23. Winkelmann J, Pagotto U, Theodoropoulou M, et al. Retention of dopamine 2 receptor mRNA and absence of the protein in craniospinal and extracranial metastasis of a malignant prolactinoma: a case report. Eur J Endocrinol. 2002;146:81-88.
24. Grossrubatscher E, Veronese S, Ciaramella PD, et al. High expression of dopamine receptor subtype 2 in a large series of neuroendocrine tumors. Cancer Biol Ther. 2008;7:1970-1978.
25. Unland R, Kerl K, Schlosser S, et al. Epigenetic repression of the dopamine receptor D4 in pediatric tumors of the central nervous system. J Neurooncol. 2014;116:237-249.
26. Sutton LP, Rushlow WJ. The dopamine D2 receptor regulates Akt and GSK-3 via Dvl-3. Int J Neuropsychopharmacol. 2012;15:965-979.
27. Radl DB, Ferraris J, Boti V, et al. Dopamine-induced apoptosis of lactotropes is mediated by the short isoform of D2 receptor. PLoS One. 2011;6(3):e18097. doi:10.1371/journal.pone.0018097.
28. Naseer MI, Ullah I, Rasool M, et al. Downregulation of dopamine D1 receptors and increased neuronal apoptosis upon ethanol and PTZ exposure in prenatal rat cortical and hippocampal neurons. Neurol Sci. 2014;35(11):1681-1688.
29. Dalton SO, Mellemkjaer L, Thomassen L, et al. Risk for cancer in a cohort of patients hospitalized for schizophrenia in Denmark, 1969-1993. Schizophr Res. 2005;75:315-324.
30. Mani SA, Guo W, Liao MJ, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 2008;133:704-715.
31. Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell. 2009;139:871-890.
32. Kessenbrock K, Plaks V, Werb Z. Matrix metalloproteinases: regulators of the tumor microenvironment. Cell. 2010;141:52-67.